Angion Biomedica Corp.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Angion Biomedica Corp. generated cash of -$32,694,000, which is more than the previous year. Cash used in financing activities reached the amount of $38,613,000 last year. Net change in cash is therefore $5,887,000.
Cash Flow
| 2012 | 1.06M | -47.73K | -429.22K |
|---|---|---|---|
| 2013 | 1.89M | -67.57K | -1.17M |
| 2018 | -8.02M | 0 | 31.74M |
| 2019 | -24.58M | -242K | 4.89M |
| 2020 | -22.88M | -41K | 52.40M |
| 2021 | -52.64M | -382K | 107.17M |
| 2022 | -38.39M | 0 | -60K |
| 2023 | -32.69M | -32K | 38.61M |
ANGN Cash Flow Statement (2012 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 8.41M | 88.75M | 34.60M | 5.57M | 25.51M | 1.79M | 1.40M | 816.26K |
Operating activities | ||||||||
Net income | -35.19M | -38.80M | -54.57M | -80.10M | -40.65M | -20.02M | 632.24K | 307.30K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 1.17M | 991K | 801K | 628K | 496K | 2K | 460.34K | 463.21K |
Stock-based compensation expense | 0 | 885K | 12.04M | 4.71M | 3.33M | 0 | 0 | 140 |
| Deferred income tax benefit | 0 | 885K | 12.04M | 4.71M | 3.33M | 0 | 0 | 140 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 440K | -333K | 180K | 0 | 0 |
Inventories | 0 | 0 | 0 | 1.12M | -241K | 2.28M | 0 | 0 |
Accounts payable | 23K | -2.05M | -866K | -5.60M | 10.70M | 449K | -171.89K | 103.49K |
Cash generated by operating activities | -32.69M | -38.39M | -52.64M | -22.88M | -24.58M | -8.02M | 1.89M | 1.06M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -50K | 0 |
Investments In Property Plant And Equipment | -66K | 0 | -382K | -41K | -242K | 0 | -17.57K | -47.73K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -32K | 0 | -382K | -41K | -242K | 0 | -67.57K | -47.73K |
Financing activities | ||||||||
Common Stock Issued | 111.06M | 0 | 107.48M | 20.04M | 0 | 28.59M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | -1.05M | -312.00K |
Repurchases of common stock | 6.99M | 0 | -10K | -36K | -286K | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -9K | 0 | 0 | 0 | -115.58K | -108.50K |
Cash used in financing activities | 38.61M | -60K | 107.17M | 52.40M | 4.89M | 31.74M | -1.17M | -429.22K |
Net Change In Cash | 5.88M | -38.26M | 54.14M | 29.03M | -19.94M | 23.72M | 652.75K | 588.22K |
Cash at end of period | 14.30M | 50.48M | 88.75M | 34.60M | 5.57M | 25.51M | 2.05M | 1.40M |
| Data source | Data source | Data source | Data source |